Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) General Counsel Martin Wilson Sells 1,175 Shares of Stock

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) General Counsel Martin Wilson sold 1,175 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $13.05, for a total transaction of $15,333.75. Following the completion of the transaction, the general counsel now owns 63,560 shares of the company’s stock, valued at $829,458. This trade represents a 1.82 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Rocket Pharmaceuticals Stock Down 0.1 %

Shares of NASDAQ RCKT opened at $14.10 on Tuesday. Rocket Pharmaceuticals, Inc. has a 52-week low of $12.62 and a 52-week high of $32.53. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05. The stock has a market cap of $1.29 billion, a P/E ratio of -5.13 and a beta of 1.09. The firm has a 50 day moving average price of $17.15 and a 200 day moving average price of $19.83.

Hedge Funds Weigh In On Rocket Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Novo Holdings A S raised its stake in Rocket Pharmaceuticals by 4.8% during the 2nd quarter. Novo Holdings A S now owns 1,100,000 shares of the biotechnology company’s stock worth $23,683,000 after buying an additional 50,000 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Rocket Pharmaceuticals during the second quarter worth about $2,144,000. First Turn Management LLC raised its position in shares of Rocket Pharmaceuticals by 10.8% during the third quarter. First Turn Management LLC now owns 621,306 shares of the biotechnology company’s stock worth $11,476,000 after purchasing an additional 60,317 shares during the period. Maverick Capital Ltd. lifted its holdings in shares of Rocket Pharmaceuticals by 1.0% during the 2nd quarter. Maverick Capital Ltd. now owns 3,928,312 shares of the biotechnology company’s stock valued at $84,577,000 after purchasing an additional 40,000 shares in the last quarter. Finally, Westfield Capital Management Co. LP grew its position in shares of Rocket Pharmaceuticals by 3.8% in the 3rd quarter. Westfield Capital Management Co. LP now owns 4,493,833 shares of the biotechnology company’s stock valued at $83,001,000 after purchasing an additional 165,911 shares during the period. Institutional investors and hedge funds own 98.39% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on RCKT shares. Canaccord Genuity Group reissued a “buy” rating and issued a $39.00 target price on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. JPMorgan Chase & Co. boosted their price objective on Rocket Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and set a $52.00 target price on shares of Rocket Pharmaceuticals in a research report on Tuesday, November 19th. Leerink Partners lowered their price target on shares of Rocket Pharmaceuticals from $46.00 to $44.00 and set an “outperform” rating for the company in a research report on Tuesday, November 19th. Finally, Chardan Capital reissued a “buy” rating and set a $62.00 price target on shares of Rocket Pharmaceuticals in a research note on Monday, November 18th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Rocket Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $51.00.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.